ArticleCancer imaging : the official publication of the International Cancer Imaging Society2025
PSMA expression assessed by [
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPSMA PET/CT (Prostate-specific membrane antigen positron emission tomography / computed tomography) has revolutionized prostate cancer imaging. While PSMA expression is influenced by androgen receptor pathway inhibitors (ARPI), few studies have examined the specific effects of apalutamide, a widely used ARPI for hormone-sensitive metastatic prostate cancer. This study evaluated the impact of apalutamide on PSMA radioligand uptake.
methodsWe evaluated 17 patients with metastatic hormone-sensitive prostate cancer (mHSPC) who underwent [18F]PSMA-1007 PET/CT imaging prior to (PET1) (time from PET1 to initiation of apalutamide: 0.40 months; range 0.03–5.90 months) and during apalutamide treatment (PET2) (time from apalutamide initiation to PET2: 5.30 months; range 1.70–20.30 months). Biodistribution and tumor uptake were calculated using whole body total tumor volume (TTV), TTV-SUVmax and TTV-SUVmean and changes between imaging time points were analysed.
resultsAll patients demonstrated significant clinical and biochemical PSA responses after treatment initiation (median PSA (ng/mL) 46.40 vs. 0.03, p = 0.001). On PSMA PET/CT during apalutamide therapy, patients showed an overall decrease in TTV-SUVmax, TTV-SUVmean and TTV. Median decreases in TTV-SUVmax and TTV-SUVmean were − 54% and − 28%, respectively (p = 0.006, p = 0.020). TTV exhibited a significant median decrease by -53% (p = 0.006). In 4/17 (23.5%) patients imaging and biochemical response revealed discordant results.
conclusionsThis pilot study indicates that, in mHSPC patients, PSMA upregulation is unlikely with intermediate to long-term apalutamide therapy. However, an increase of imaging parameters with synchronous decrease of PSA levels should raise suspicion of early imaging progression, resulting in close monitoring. Further research is warranted to explore early treatment response in the hormone-sensitive stadium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.